Pfizer Ltd. — Regulatory Filings 2023

May 18, 2023

==> picture [94 x 39] intentionally omitted <==

Pfizer Limited

The Capital, 1802/1901,

Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

May 18, 2023

The Corporate Relationship Dept. The Manager, Listing Dept. BSE Limited The National Stock Exchange of India Ltd. 1[st] Floor, P.J.Towers Exchange Plaza, 5[th] Floor Plot No. C/1, G Block Dalal Street, Fort Bandra-Kurla Complex, Bandra (E) Mumbai – 400 001 Mumbai – 400 051 Scrip Code: 500680 Scrip Symbol: PFIZER

Dear Sirs / Madam,

Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“LODR Regulations”), we hereby inform you that, the Company has decided to initiate a voluntary recall of( i) Magnex 1gm, 2gm; (ii) Magnex Forte 1.5gm, 3gm; (iii) Zosyn 4.5gm; and (iv) Magnamycin 250mg, 1gm, 2gm injections (“ Products ”) manufactured by Astral SteriTech Private Limited (“ Astral ”) and marketed/distributed by Pfizer Limited (" the Company ”).

Pfizer places the utmost emphasis on patient safety and product quality at every step in the manufacturing and supply chain process.

The Company was informed by its contract manufacturer in India, Astral SteriTech Private Ltd, that it has observed an out-of-specification during a routine environmental monitoring of its manufacturing block. Astral manufactures three products for Pfizer, namely, Magnex, Magnamycin and Zosyn. While this issue is presently being investigated, out of an abundance of caution, Pfizer has decided to voluntarily recall from the market, all batches of these three products.

Pfizer is taking all necessary steps to resolve the situation. The above voluntary recall is likely to have an impact on the revenue and profitability of the Company. The said Products recorded a sale of Rs. 139 crores for the year ended on March 31, 2023.

This intimation is also being made available on the website of the Company at www.pfizerltd.co.in

We request you to kindly take the same on record.

Thanking you,

Yours truly, For Pfizer Limited PRAJEET Digitally signed by PRAJEET NAIR NAIR Date: 2023.05.18 19:28:07 +05'30'

Prajeet Nair

Director – Corporate Services & Company Secretary

CIN: L24231MH1950PLC008311 Email ID: contactus.india@pfizer.com Website: www.pfizerltd.co.in